Repertoire Immune Medicines Secures $189M Financing

Cambridge biotech Repertoire Immune Medicines has completed a $189 million Series B financing. The company is focused on decoding the immune synapse to create novel immune therapies for cancer, immune disorders, infectious disease, and other serious diseases. Proceeds from this financing will support further expansion of the company’s proprietary DECODE discovery platform, accelerate its clinical and preclinical pipeline, expand Repertoire’s team, and enhance its manufacturing capabilities. Founded by Flagship Pioneering in 2019, Repertoire has raised more than $350 million in the aggregate to date.

“We are making tremendous progress toward unlocking the full potential of therapeutically modulating the immune system by decoding the interactions between T cells and antigens to create new classes of immune medicines for cancer, immune disorders, infectious diseases, and other serious diseases,” said John Cox, CEO of Repertoire. “This financing round will support the broad application of our DECODE platform to define and understand the complete repertoire of T cell receptor-antigen pairs that drive cellular immunity. The insights we glean from this information will enable a new era of novel immune medicines designed to exploit these critical interactions.” This financing will also support the advancement of multiple clinical programs in immuno-oncology using Repertoire’s proprietary antigen-primed multi-clonal cytokine enhanced T cell products in solid tumors. (Source: Repertoire Immune Medicines Website, 13 April, 2021)